



Supplemental Figure 2. circMGA as a predictive biomarker for adjuvant immunotherapy in bladder cancer.

(A) Overall survival (OS) of bladder cancer patients (all patients, pathological tumor stage \leq pT2, pT3/4) treated with adjuvant immunotherapy was analyzed by Kaplan–Meier curves. Red, group of high circRNA expression. Blue, group of low circRNA expression. We used the maximally selected rank statistics method to determine the cutoff. The minimal proportion for optimal cutoff was set as 0.4. P value was calculated using a log-rank test. (B) Overall survival (OS) of bladder cancer patients (all patients, early-stage tumors (\leq pT2) and advanced-stage tumors (pT3/4)) treated with adjuvant immunotherapy was analyzed by Kaplan–Meier curves. Red, group of high circRNA expression. Blue, group of low circRNA expression. We used the maximally selected rank statistics method to determine the cutoff. The minimal proportion for optimal cutoff was set as 0.4. P value was calculated using a log-rank test. (C) Boxplot visualizing the association of circMGA subgroups for patients receiving adjuvant immunotherapy with CD8 T cells signature.